Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206466 · ClinicalTrials.gov registry record · Phase 2
Biologic Correlative Taxotere/AC
A Phase 2 study, sponsored by Baylor Breast Care Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00206466 is a Phase 2 study that has completed, run by Baylor Breast Care Center. The registered enrollment target is 70 participants.
The verdict
NCT00206466, a Phase 2 study, has completed, sponsored by Baylor Breast Care Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
We are asking you to take part in a research study of biomarkers (characteristics or traits of the genes inside cancer cells). We want to learn if these biomarkers could help us learn how well your breast cancer may respond (improve) to chemotherapy (drugs to treat cancer).
Interventions
- DRUG Taxotere
- DRUG Adriamycin/cytoxan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2002-04 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206466
The ClinicalTrials.gov registry entry for NCT00206466 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Breast Care Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Taxotere is the first listed.
NCT00206466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206466 about?
NCT00206466 is a clinical study titled "Biologic Correlative Taxotere/AC". We are asking you to take part in a research study of biomarkers (characteristics or traits of the genes inside cancer cells). We want to learn if these biomarkers could help us learn how well your breast cancer may respond (improve) to chemotherapy (drugs to treat cancer).
What is the current status of trial NCT00206466?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2002-04. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00206466?
The interventions under investigation include: Taxotere (DRUG), Adriamycin/cytoxan (DRUG).
Who is sponsoring clinical trial NCT00206466?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.